Biomarker | Lovastatin+PILI | Placebo+PILI | Between-group comparison | ||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | Post | Within-group: baseline vs. post | Baseline | Post | Within-group: baseline vs. post | Baseline | Post | Post, adjusted for baseline | |
MMP | 6.36 ± 2.84 | 6.25 ± 2.48 | t(11) = − 0.09 (0.9313) | 6.69 ± 3.65 | 7.20 ± 4.10 | t(12) = − 0.99 (0.3407) | F(1, 24) = 0.01 (0.9383) | F(1, 23) = 0.18 (0.675) | F(1, 22) = 0.48 (0.4935) |
ERK | 0.48 ± 0.26 | 0.58 ± 0.32 | t(11) = − 0.62 (0.5502) | 0.50 ± 0.22 | 0.84 ± 0.98 | t(12) = − 1.16 (0.2676) | F(1, 23) = 0.16 (0.6911) | F(1, 23) = 0.57 (0.4599) | F(1, 22) = 0.64 (0.4332) |
S6K | 0.11 ± 0.10 | 0.11 ± 0.11 | t (11) = 1.11 (0.2891) | 0.14 ± 0.26 | 0.08 ± 0.04 | t(11) = 0.66 (0.5203) | F(1, 23) = 0.08 (0.7772) | F(1, 22) = 0.07 (0.7878) | F(1, 21) = 0.09 (0.772) |